Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Sterile Compounding Update: Laws, Regulations & Standards (Law)


Description:
The purpose of this activity is to educate pharmacists on recent changes in laws, regulations and standards specific to sterile compounding with an emphasis on the new USP Chapter 800 Hazardous Drug Handling in Healthcare Settings.

Objectives:

  1. Discuss the key elements of the Drug Quality & Security Act as it relates to pharmacy practice.
  2. Summarize the key changes in the revised USP Chapter 797 and their implications for pharmacy practice.
  3. Recognize the key changes required as part of the new USP Chapter 800.
  4. Review existing and proposed state legislation in the New England area directed toward sterile compounding.
Activity Number:
0280-0000-16-082-H03-P

This recorded activity is a based on a live program that was offered on October 14, 2016 in Burlington, MA.  
Participants who received credit for the live program should not claim credit for this web based presentation.
 
System Requirements for Participants:
Operating system:  Windows XP, Vista or 7  MAC OS X  Latest Version of Adobe Reader
Browser Internet Explorer 8.0 or above  Google Chrome 16.0 or above  Firefox 7.0 or above  Safari 5.0 or above
 

Fee

$0.00

CE Hours

1.25

CE Units

0.125

Activity Type

  • Knowledge Based

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
American Health Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

  • Complete the pre-test
  • Review the content of this activity
  • Successfully complete the post-test with a score of 80% or higher 
  • Complete the activity evaluation
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation is completed.
 
Pharmacists - Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits will NOT be reported.

Support/Credits

Disclosures:
James A Jorgenson, RPh, MS, FASHP; CEO, Visante Inc.
Mr. Jorgenson is on the speaker’s bureau of Novartis
  
The reviewer is Susanne E Liewer, PharmD, BCOP; Clinical Pharmacy Coordinator, Stem Cell Transplant, The Nebraska Medical Center, Omaha, Nebraska
Dr Liewer does not have any relevant financial relationships with any commercial interests.
 
Support for This Activity:
This activity is supported by the Association of Community Cancer Centers (ACCC)
 
American Health Resources assesses conflict of interest with its instructors, reviewers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are resolved by American Health Resources for fair balance and scientific objectivity.
 
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  American Health Resources does not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of American Health Resources.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

 

The purpose of this activity is to educate pharmacists on recent changes in laws, regulations and standards specific to sterile compounding with an emphasis on the new USP Chapter 800 Hazardous Drug Handling in Healthcare Settings.
 

Objectives

  • Discuss the key elements of the Drug Quality & Security Act as it relates to pharmacy practice.
  • Summarize the key changes in the revised USP Chapter 797 and their implications for pharmacy practice.
  • Recognize the key changes required as part of the new USP Chapter 800.
  • Review existing and proposed state legislation in the New England area directed toward sterile compounding.

Speaker(s)/Author(s)

James A. Jorgenson, MS, RPh, FASHP picture

James A. Jorgenson, MS, RPh, FASHP
Chief Executive Officer and Board Chair, Visante, Inc. and Visante Limited


Brief Bio : Jim Jorgenson is CEO of Visante where he leads national and international programs for medicines management improvement in the US, UK and Canada. His more than 30-year career includes pharmacy oversight of very large health systems and their network associations as well as academic leadership in graduate pharmacy education. Previous to joining Visante Jim was Vice President, Chief Pharmacy Officer for Indiana University Health (IU Health), the largest and most comprehensive state-based healthcare system in Indiana. Previous to joining Indiana University Health, Jim was Administrative Director of Pharmacy Services for the University of Utah Health Care and Associate Dean for Pharmacy at the University of Utah College of Pharmacy in Salt Lake City. He also directed pharmacy services for the 2002 Winter Olympic games in Salt Lake City. Jim's leadership has also extended to professional organizations and societies where he has served on numerous councils and committees for the American Society of Health System Pharmacists (ASHP) and is a faculty member for the ASHP Foundation Pharmacy Leadership Academy. In 2008 he received the ASHP Award for Distinguished Leadership of Health-Systems Pharmacy Practice.

Activity Number

0280-0000-16-082-H03-P

Release Date: Nov 10, 2016
Credit Expiration Date: Nov 10, 2018

CE Hours

1.25

Fee

$0.00